Drugs similar to tofisopam tianeptine for depression
Reading File
Finding Sources
Finding Sources
Searching PubMed
tofisopam anxiolytic mechanism depression
Searching PubMed
tianeptine depression mechanism antidepressant
Searching the Web
drugs similar to tofisopam tianeptine depression anxiolytic novel mechanism
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
agomelatine vortioxetine depression novel mechanism
Finding Sources
Finding Sources
Reading File
Finding Sources
I now have enough information for a thorough, well-organized answer. Let me compile it.
Drugs Similar to Tofisopam & Tianeptine for Depression
These two drugs sit outside mainstream antidepressant classes. Here is a breakdown of each drug's mechanism and what other agents share similar pharmacological territory.
Tofisopam (Grandaxin)
Class: 2,3-benzodiazepine (NOT a classic 1,4-benzodiazepine)
Mechanism: Unlike classical benzodiazepines (which enhance GABA-A), tofisopam works primarily by inhibiting phosphodiesterase (PDE) enzymes - mainly PDE4 and PDE10 - raising intracellular cAMP levels. This produces anxiolytic and mild antidepressant-like effects without sedation, muscle relaxation, or addiction. It also mildly modulates dopamine in the striatum and reduces sympathetic outflow.
Drugs with similar mechanisms:
| Drug | Shared Mechanism | Notes |
|---|---|---|
| Roflumilast | PDE4 inhibitor | Licensed for COPD; shown antidepressant-like activity in preclinical studies |
| Rolipram | PDE4 inhibitor | Research tool compound; early human trials showed antidepressant efficacy but side effects limited use |
| Cilostazol | PDE3 inhibitor | Used for peripheral artery disease; some mood-stabilizing/neuroprotective data |
| Tandospirone / Buspirone | 5-HT1A partial agonist (also reduces sympathetic tone, no GABA dependence) | Non-sedating anxiolytic with some antidepressant activity; no benzodiazepine receptor action |
| Etifoxine | GABAergic via neurosteroid pathway (distinct from BZD site) + mitochondrial TSPO | Non-sedating anxiolytic, no dependence risk - functionally similar profile to tofisopam |
The 2022 study by Turan Yucel et al. confirmed antidepressant-like effects of tofisopam in mice via behavioral and molecular docking work, and the Murthy & Mangot 2015 review covers the psychiatric applications of PDE inhibition broadly.
Tianeptine (Stablon/Coaxil)
Class: Atypical tricyclic antidepressant (does NOT inhibit serotonin reuptake - it actually enhances it in the original model, but this is now considered a minor effect)
Mechanism: Tianeptine is now understood to act as a mu-opioid receptor (MOR) agonist at therapeutic doses, and also modulates glutamate (AMPA/NMDA) receptors and promotes neuroplasticity/hippocampal neurogenesis. This distinguishes it sharply from SSRIs - it does not raise extracellular serotonin and does not bind to >100 classical neuroreceptors. At high/abuse doses it behaves like an opioid, which has made it a drug of misuse (Harrison's, 2025 edition; Kaplan & Sadock's Comprehensive Textbook).
Drugs with similar mechanisms:
| Drug | Shared Mechanism | Notes |
|---|---|---|
| Ketamine / Esketamine (Spravato) | NMDA glutamate receptor antagonism → rapid antidepressant, neuroplasticity | FDA-approved for treatment-resistant depression (TRD); rapid onset (hours) |
| Dextromethorphan/Bupropion (Auvelity) | NMDA antagonism + dopamine/NE reuptake inhibition | FDA-approved 2022 for MDD; shares tianeptine's glutamatergic mechanism |
| Agomelatine (Valdoxan) | Melatonin MT1/MT2 agonism + 5-HT2C antagonism; promotes neuroplasticity | Non-monoaminergic antidepressant; used in Europe; zero sexual dysfunction |
| Vortioxetine (Trintellix) | Multimodal: SERT inhibition + 5-HT receptor modulation (1A, 1B, 3, 7 antagonism) | Shown in head-to-head comparisons to outperform several SSRIs; also improves cognition |
| Buprenorphine/Samidorphan (Brixia) | Opioid partial agonism (mu/kappa modulation) - directly shares tianeptine's MOR mechanism | Used as adjunct in TRD; shares tianeptine's opioid pathway |
| Brexanolone / Zuranolone | GABA-A neurosteroid modulation → restores neuroplasticity | Approved for postpartum depression; novel non-monoaminergic |
| Mirtazapine (Remeron) | NaSSA: alpha-2 antagonism, 5-HT2/3 antagonism; indirect NE/5-HT enhancement without reuptake inhibition | Clinically used when SSRI fails; distinct from classical TCAs |
Summary Comparison
| Drug | Key Mechanism | Available |
|---|---|---|
| Tofisopam | PDE4/10 inhibition (cAMP ↑) | Available in Eastern Europe, India; not FDA-approved |
| Tianeptine | Mu-opioid agonist + glutamate modulation | Not FDA-approved in US; used in France, Asia, Latin America |
| Esketamine | NMDA antagonism | FDA-approved (nasal spray for TRD) |
| Dextromethorphan/Bupropion | NMDA antagonism + NDRI | FDA-approved 2022 |
| Agomelatine | MT1/MT2 agonist + 5-HT2C antagonist | EMA-approved; not FDA-approved |
| Vortioxetine | Multimodal serotonergic | FDA-approved |
| Buprenorphine/Samidorphan | Opioid modulation | FDA-approved as MDD adjunct |
| Buspirone/Tandospirone | 5-HT1A partial agonist | FDA-approved (buspirone) |
Key clinical takeaway: Both tofisopam and tianeptine were developed precisely because patients and clinicians wanted effective drugs without classic benzodiazepine or SSRI side effects (no sedation, no sexual dysfunction, no dependence with tofisopam; no weight gain, no sexual dysfunction with tianeptine). The modern drugs that most closely replicate this profile are esketamine/ketamine (shared glutamatergic neuroplasticity mechanism with tianeptine), agomelatine (non-monoaminergic, neuroplasticity-promoting), and etifoxine (non-sedating, non-dependent anxiolytic-antidepressant similar in profile to tofisopam).
Note on tianeptine misuse: Harrison's (2025) flags tianeptine as an emerging drug of abuse in the US, where it is sold as a "dietary supplement." At supratherapeutic doses it produces opioid-like euphoria and physical dependence. Buprenorphine shares this mechanism intentionally (for antidepressant augmentation) but with safety guardrails. Tianeptine misuse/withdrawal should be managed like opioid withdrawal.
This is a shared conversation. Sign in to Orris to start your own chat.